Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07076407 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

Study acronym: X-NOVA3
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 48 to 50v11
  2. Trial sites expanded: 44 → 48 locationsv10
  3. Study sites: 42 to 44v9
  4. Trial sites expanded: 35 → 42 locationsv8
  5. Study sites: 30 to 35v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 24 to 30v6
  2. Study sites: 16 to 24v5
  3. Study sites: 9 to 16 Eligibility criteria expanded, about 7 words · Secondary endpoints: 3 to 4v4 Show 2 more changesShow less
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: 3 to 4

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 3 to 9v3
  5. Study sites: 1 to 3v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Trial Details
NCT Number NCT07076407
Lead Sponsor Xenon Pharmaceuticals Inc.
Conditions Major Depressive Disorder
Enrollment 450 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov